Veneno Technologies is pleased to announce the full renewal of our official website, created to communicate our mission and progress more clearly and to a broader audience. The redesigned website features a more intuitive and engaging experience, showcasing the potential of disulfide-rich peptides (DRPs) enabled by our proprietary platform, along with the authentic voices of […]

“Transforming venom, one of nature’s most powerful bioactive substances, into hope for humanity.” That is the bold mission driving Veneno Technologies. Led by President and CEO Takatoshi Kuno, the company is working to break through the limitations of conventional drug discovery with its proprietary peptide engineering technologies. Together with partners around the world, Veneno is […]

In the turbulent world of biotech startups, Veneno Technologies has carved out a distinctive position of its own. At the heart of that achievement lies Director and CTO Tadashi Kimura’s uncompromising devotion to technology, a commitment he has sustained over many years. Since the company’s founding, Kimura has remained at the forefront of its research, […]

Hiroo Tanaka, who is translating deep academic expertise into real-world applications, and Takumi Okamoto, who is channeling the untapped potential of plants into innovation in agriculture. These two young researchers, each with a different area of specialization, are using Veneno Technologies’ platform as a powerful tool to push beyond conventional boundaries and open new frontiers […]

With more than a decade of experience in molecular microbiology and genetic engineering, Huong Minh Nguyen is pursuing the potential of disulfide-rich peptides (DRPs) at Veneno Technologies. What drives her is a simple yet powerful belief: that genuine curiosity can connect people across borders and disciplines. Here, we take a closer look at her philosophy […]

The Challenge Embraced by the Young Researchers Thriving at Veneno At Veneno Technologies, we are transforming nature’s venoms into breakthrough medicines. Armed with our proprietary platform, it is the passionate young researchers who are stepping into unexplored frontiers in biotechnology. Here, we take a closer look at the stage on which the next generation of […]

Veneno Technologies has entered into a business alliance with Molmir Inc., a company with strong expertise in identifying and refining drug discovery seeds originating from academia, to build a new commercialization model that ensures academic drug discovery does not end at the research stage. As academia-originated ventures are becoming increasingly central players in drug discovery, […]

Veneno Technologies has launched a joint research collaboration with Alpha Fusion Inc. and Mitsubishi Tanabe Pharma Corporation to develop innovative cancer therapeutics. By leveraging our proprietary peptide technologies, we aim to accelerate the development of next-generation radiopharmaceuticals that precisely target cancer cells. This collaboration will focus on the research and development of novel astatine-211-labeled radiopharmaceuticals […]

Veneno Technologies has launched a joint research collaboration with Alpha Fusion Inc. and Mitsubishi Tanabe Pharma Corporation to develop innovative cancer therapeutics. By leveraging our proprietary peptide technologies, we aim to accelerate the development of next-generation radiopharmaceuticals that precisely target cancer cells. This collaboration will focus on the research and development of novel astatine-211-labeled radiopharmaceuticals […]